Member Info for thevid

This sums it up pretty well.

https://mhmembers.com/if-aim-is-a-casino-can-you-beat-the-house/

life is priceless in my book.

Yet you spend all day on here loool

Cheers Tim.

Am i reading this right, under who else is applying . Patients from California used in p1 ? sorry if already known and i missed it.

https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477#eligibilityCriteria

5. Fast Track Approval and/or similar.

Quite possible we are after one of these.
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation

How you must envy those stopped clocks.

Good example of process. And reassuring to have the team Vlad has built around him.

https://www.hallorancg.com/2021/04/13/cell-and-gene-therapy-initial-ind-submission-considerations/

https://www.thefdagroup.com/blog/a-basic-guide-to-iq-oq-pq-in-fda-regulated-industries

https://uraholdingsplc.co.uk/investors/publications/, under the Company Documents tab.

https://usamriid.health.mil/aboutpage.htm

https://www.pointbiopharma.com/our-products/pipeline/canseek

Reading MyHealthChecked PLC (AIM: MHC) RNs looks like Launch is a real bargain.
Considering we got large discount on covid sales.
This better-than-expected performance was driven by the demand for COVID Lateral Flow tests ("LFTs") COVID testing remains the largest revenue stream for MyHealthChecked, and demand is expected to continue during 2023.

It was the antibody that failed in lft. Did anyone get to the bottom of why an antibody was included along with Affimer which didn`t fail ?

i`d stick to rape and pillage if i were you.

I`m still getting over Mri thinking pumpky big trader.

He`s disrupted the board, like he set out to do. Best ignored.

@hfh, Yes i agree. I note Vlad been tweeting alot about A.I lately.

Copied this from David Chan MD:
In cancer clinical trials, if a study drug proves to be effective, patients who are benefiting are permitted to continue that drug even after the trial is completed.

I had a patient who was having a great response on a trial that turned out to be negative. The study drug was no better than standard treatment.

Yet, for that individual patient, the study drug effectively controlled her cancer and the pharmaceutical company allowed her to continue that medication for over 4 years even after the research was stopped and the experiment drug was shelved. Eventually it stopped working and I switched her to standard treatment.

Good read. A.I, T-cells

https://pharmaphorum.com/views-and-analysis/jpm2023-breakthroughs-await-but-so-do-roadblocks/